CareLit · DOI-Nachweis · Klinische Pädiatrie
Targeting the interaction of HDAC2 and MYC in Group 3 medulloblastoma
DOI 10.1055/s-0036-1593553
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ Ecker, I Oehme, F Selt, M Kool, M Schnölzer, U Warnken, S Brabetz, R Wechsler-Reya, AE Kulozik, SM Pfister, O Witt, T Milde
ZeitschriftKlinische Pädiatrie
Ausgabe11/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Patients with high-risk subgroup medulloblastoma (MB) show poor overall survival rates despite aggressive treatment while survivors suffer from important treatment-associated morbidity. Particularly poor outcome is observed in patients with tumors of the molecular subgroup Group 3 with an amplification and high levels of the transcription factor MYC. We have previously shown that Group 3 MB cell lines with MYC ampli…
Zitieren
Zitierempfehlung
J Ecker, I Oehme, F Selt, M Kool, M Schnölzer, U Warnken, S Brabetz, R Wechsler-Reya, AE Kulozik, SM Pfister, O Witt, T Milde (2016) Targeting the interaction of HDAC2 and MYC in Group 3 medulloblastoma. Klinische Pädiatrie (11). https://doi.org/10.1055/s-0036-1593553
Mit CareLit weiterarbeiten